 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
3 News |  |
- |||||| GB241 (rituximab biosimilar) / Nanjing Yoko Biomedical, Walvax
Enrollment open, Trial completion date: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients (clinicaltrials.gov) - Feb 20, 2024
P3, N=360, Recruiting, Sponsor: Nanjing Yoko Biomedical Co., Ltd.
Unknown status --> Recruiting | Trial completion date: Oct 2021 --> Dec 2025
- ||| GB241 (rituximab biosimilar) / Nanjing Yoko Biomedical, Walvax
Trial completion: A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 23, 2021
P1, N=85, Completed, Sponsor: Nanjing Yoko Biomedical Co., Ltd.
Unknown status --> Recruiting | Trial completion date: Oct 2021 --> Dec 2025 Recruiting --> Completed
- | GB241 (rituximab biosimilar) / Nanjing Yoko Biomedical, Walvax
New P3 trial: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients (clinicaltrials.gov) - Aug 29, 2018
P3, N=360, Not yet recruiting, Sponsor: Nanjing Yoko Biomedical Co., Ltd.
- ||| GB241 (rituximab biosimilar) / Nanjing Yoko Biomedical, Walvax
New P1 trial: A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 27, 2016
P1, N=80, Recruiting, Sponsor: Nanjing Yoko Biomedical Co., Ltd.